Dr. Grosser's lab studies the human biology of inflammation and the translational therapeutics of lipid mediators. He is interested in understanding how the benefit of drugs targeting lipid mediators (e.g. NSAIDs) can be exploited while managing or avoiding their adverse effects. If this can be established for NSAIDs, where there is a subtle trade-off between benefit and risk at the population level (but less subtle at the individual level), it may serve as a general paradigm for the personalization of other commonly used classes of drugs. Dr. Grosser conducts human deep-phenotyping trials designed to elucidate genomic and non-genomic variability in the response to drugs. He studies molecular mechanisms using genomics, proteomics, lipidomics approaches in humans and model organisms.